- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00030394
Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
A Phase II Study of Gleevec in Ph+ Chronic Phase Chronic Myelogenous Leukemia
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
I. Determine the response rate in patients with Philadelphia chromosome positive chronic phase chronic myelogenous leukemia treated with imatinib mesylate.
II. Determine the disease-free survival of patients treated with this drug. III. Determine the pharmacokinetics of this drug in these patients. IV. Determine the toxic effects of this drug in these patients. V. Determine the rates of hematological, cytogenetic, and molecular response and time to response in patients treated with this drug.
OUTLINE: This is a multicenter study. Patients are stratified according to disease (chronic myelogenous leukemia [CML] in first chronic phase after failing interferon therapy or demonstrating intolerance to interferon [closed to accrual as of 12/05/03] vs CML relapsing after stem cell transplantation or in second or subsequent chronic phase [closed to accrual as of 7/29/05] vs newly diagnosed CML in first chronic phase with no prior treatment [closed to accrual as of 7/29/05] vs newly diagnosed CML in first chronic phase with no prior treatment).
Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.
PROJECTED ACCRUAL: A total of 109 patients (30 for stratum I [closed to accrual as of 12/05/03] and stratum II [closed to accrual as of 7/29/05], 34 for stratum III [closed to accrual as of 7/29/05], and 45 for stratum IV) will be accrued for this study within 2 years.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
Arcadia, California, Forenede Stater, 91006-3776
- Children's Oncology Group
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosis of Philadelphia chromosome positive (Ph+) chronic phase chronic myelogenous leukemia (CML)
Stratum I (closed to accrual as of 12/05/03):
CML in first chronic phase with resistance to interferon alfa (IFN-A) therapy defined as one of the following:
- WBC count at least 20,000/mm^3 after at least 3 months of treatment with an IFN-A-containing regimen
- Rising WBC count (at least 100% increase to a level of at least 20,000/mm^3) by two samples at least two weeks apart while receiving treatment with an IFN-A-containing regimen
- At least 66% Ph+ cells in bone marrow after 1 year of IFN-A therapy
- At least 30% increase in Ph+ cells in bone marrow after IFN-A-induced cytogenetic response while continuing to receive IFN-A therapy
- Intolerance to interferon therapy defined as more than two grade 2 toxic effects or any grade 3 toxic effect related to interferon therapy, except grade 3 fever, that is persistent beyond the first 28-day course of therapy and unresponsive to standard supportive care interventions
Stratum II (closed to accrual as of 7/29/05): CML recurring after stem cell transplantation or in second or subsequent chronic phase
- No molecular relapse (only evidence is detection of bcr-abl rearrangement with normal bone marrow and blood morphology and normal standard cytogenetic analysis)
- Stratum III (closed to accrual as of 7/29/05): Newly diagnosed CML in first chronic phase with no prior treatment except hydroxyurea
- Stratum IV: Newly diagnosed CML in first chronic phase with no prior treatment except hydroxyurea
No accelerated or blast phase defined as one or more of the following:
- WBC doubling time less than 5 days
- Chloroma
- Medullary fibrosis
- More than 10% blasts in peripheral blood or bone marrow
- More than 20% promyelocytes in peripheral blood or bone marrow
- More than 20% basophils and eosinophils in peripheral blood
- Performance status - ECOG 0-2
- At least 8 weeks
- See Disease Characteristics
- Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram
- Bilirubin no greater than 1.5 times normal
- ALT less than 3.0 times normal
- Albumin greater than 2 g/dL
- Creatinine no greater than 1.5 times normal
- Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No uncontrolled infection
- No CNS toxicity greater than grade 2
- See Disease Characteristics
- No prior immunotherapy (for patients in stratum III [closed to accrual as of 7/29/05] and stratum IV only)
- At least 3 months since prior stem cell transplantation (SCT) (patients with allogeneic SCT must have no active graft-versus-host disease [GVHD] and have stable use of steroids) (for patients in stratum II only )
- At least 1 week since prior growth factors
- At least 1 week since prior biologic therapy, including interferon alfa (for patients in stratum I [closed to accrual as of 12/05/03] and stratum II only)
- Recovered from prior immunotherapy
- No concurrent immunomodulating agents
- See Disease Characteristics
- No prior chemotherapy (for patients in stratum III [closed to accrual as of 7/29/05] and stratum IV only)
- At least 6 weeks since prior busulfan or nitrosoureas
- At least 7 days since prior hydroxyurea
- At least 7 days since prior low-dose cytarabine (less than 30 mg/m^2 every 12 to 24 hours)
- At least 14 days since prior moderate-dose cytarabine (100-200 mg/m^2 for 5 to 7 days)
- At least 28 days since prior high-dose cytarabine (1-3 g/m^2 every 12 to 24 hours for 6 to 12 doses)
- At least 21 days since all other cytotoxic chemotherapy
- Recovered from prior chemotherapy
- No concurrent chemotherapy
- No concurrent steroids other than for controlled GVHD in patients with prior allogeneic SCT
- No prior radiotherapy (for patients in stratum III [closed to accrual as of 7/29/05] and stratum IV only)
- At least 2 weeks since prior local palliative (small port) radiotherapy*
- At least 3 months since prior craniospinal radiotherapy or radiotherapy to 50% or more of pelvis*
- At least 6 weeks since prior substantial bone marrow radiotherapy*
- Recovered from prior radiotherapy
- No prior imatinib mesylate
- No concurrent enzyme-activating anticonvulsants
- No concurrent warfarin
- No concurrent naturopathic agents or herbal medicines
- No other concurrent investigational agents
- Concurrent low-molecular weight heparin allowed
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Treatment (imatinib mesylate)
Patients receive oral imatinib mesylate once daily on days 1-28.
Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.
|
Korrelative undersøgelser
Korrelative undersøgelser
Andre navne:
Gives oralt
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Svarprocent
Tidsramme: Op til 5 år
|
Op til 5 år
|
Sygdomsfri overlevelse
Tidsramme: Op til 5 år
|
Op til 5 år
|
Toksiciteter klassificeret i henhold til National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0
Tidsramme: Op til 5 år
|
Op til 5 år
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Time to achieve hematological cytogenetic and molecular response
Tidsramme: Up to 12 months
|
Studied in a multivariate model using a Cox proportional hazards regression model.
|
Up to 12 months
|
Begivenhedsfri overlevelse
Tidsramme: Op til 5 år
|
Op til 5 år
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Martin Champagne, Children's Oncology Group
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter histologisk type
- Neoplasmer
- Knoglemarvssygdomme
- Hæmatologiske sygdomme
- Myeloproliferative lidelser
- Leukæmi
- Leukæmi, myeloid
- Leukæmi, myelogen, kronisk, BCR-ABL positiv
- Leukæmi, myeloid, kronisk fase
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Proteinkinasehæmmere
- Imatinib mesylat
Andre undersøgelses-id-numre
- NCI-2012-01867
- U10CA098543 (U.S. NIH-bevilling/kontrakt)
- AAML0123
- CDR0000069161 (Registry Identifier: PDQ (Physician Data Query))
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med laboratoriebiomarkøranalyse
-
Liao Jian AnRekrutteringHoved- og halskræftTaiwan
-
Fondation LenvalTrukket tilbage
-
Progenity, Inc.AfsluttetDowns syndrom | Aneuploidi | DiGeorges syndrom | Turners syndrom | Klinefelters syndrom | Kromosom sletning | Edwards syndrom | Patau syndromForenede Stater
-
IRCCS Eugenio MedeaRekrutteringAutismespektrumforstyrrelse | Tidlig indsatsItalien
-
Oregon Health and Science University4DMedicalTilmelding efter invitationLungesygdomme | KOL | Luftvejssygdom | DyspnøForenede Stater
-
IRCCS Eugenio MedeaRekrutteringCerebral Parese | Erhvervet hjerneskadeItalien
-
Modarres HospitalAfsluttetKomplikationer | Billedstyret biopsi | Nyre GlomerulusIran, Islamisk Republik
-
Healthy.io Ltd.Afsluttet
-
Medwave Estudios LimitadaAsociación Chilena de SeguridadUkendtErhvervsmæssig eksponering | Muskuloskeletal sygdomChile
-
Duke UniversityTrukket tilbageAntikoagulation og trombose Point of Care Test (AT-POCT)Forenede Stater